Captrust Financial Advisors Biohaven Pharmaceutical Holding CO Ltd. Transaction History

Captrust Financial Advisors

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 23, 2022	SELL	$83.14 - $145.99 $2,577 - $4,525	-31 Reduced 5.11%	576 $84,000
Q2 2022 Aug 16, 2022	BUY	$83.14 - $145.99 $3,076 - $5,401	37 Added 6.49%	607 $88,000
Q1 2022 May 16, 2022	SELL	$110.08 - $142.92 $550 - $714	-5 Reduced 0.87%	570 $68,000
Q4 2021 Feb 14, 2022	BUY	$99.73 - $148.48 $14,361 - $21,381	144 Added 33.41%	575 $79,000
Q3 2021 Nov 16, 2021	BUY	$98.85 - $138.91 $4,349 - $6,112	44 Added 11.37%	431 $60,000
Q2 2021 Aug 16, 2021	BUY	$65.78 - $105.02 $5,722 - $9,136	87 Added 29.0%	387 $38,000
Q1 2021 May 17, 2021	BUY	$64.07 - $91.75 $14,415 - $20,643	225 Added 300.0%	300 $21,000
Q4 2020 Feb 16, 2021	BUY	$65.07 - $98.24 $4,880 - $7,368	75 New	75 $6,000

792K

Ticker BHVN
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 71,645,000
Market Cap $3.18B
Description
Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops products candidates targeting neurological and neuropsychiatric diseases, and rare disorders in the United States. It offers NURTEC ODT (rimegepant) for the acute treatment of migraine, as well as developing Rimegepant for preventive treatment of migraine; Zavege...

Get notified when there are updates to the investment portfolio of Captrust Financial Advisors, based on Form 13F filings with the SEC.

Stay updated on Captrust Financial Advisors with notifications on news.